Patent ID: 8613916

Claim:
An immunotherapy for pancreatic cancer, which comprises the steps of: culturing peripheral blood lymphocytes of a patient with pancreatic cancer by stimulating the lymphocytes with an anti-CD3 antibody and an anti-CD52 antibody, thereby to obtain an immunotherapeutic agent, and administering at least four infusions of the immunotherapeutic agent to the same patient, wherein each of the infusions of the immunotherapeutic agent comprise at least 15×10 9 cells of activated lymphocytes, the percentage of CD3 − CD56 + NK cells in the activated lymphocytes is at least 30%, and the administration of the immunotherapeutic agent is begun for the patients with pancreatic cancer who fulfill at least one of the following immunocompromised states: (a) the number of peripheral blood lymphocytes being less than 1,000 cells/μl; (b) the number of CD3 − CD56 + NK cells in the peripheral blood lymphocytes being less than 200 cells/μl; (c) the cytotoxic activity of CD3 − CD56 + NK cells in the peripheral blood being less than 30%; and (d) the number of NKG2D + lymphocytes in the peripheral blood being less than 400 cells/μl.